Cargando…

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1

Most of the gastrointestinal stromal tumors (GISTs) have gain-of-function mutations in the KIT gene, which can be used as a prognostic marker for the biological behavior of tumors, predictive marker for the response of tyrosine kinase inhibitors, and diagnostic marker. Researchers have focused on PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Baskin, Yasemin, Kocal, Gizem Calibasi, Kucukzeybek, Betul Bolat, Akbarpour, Mahdi, Kayacik, Nurcin, Sagol, Ozgul, Ellidokuz, Hulya, Oztop, Ilhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838738/
https://www.ncbi.nlm.nih.gov/pubmed/27178821
http://dx.doi.org/10.3727/096504016X14576297492418
_version_ 1783643249616879616
author Baskin, Yasemin
Kocal, Gizem Calibasi
Kucukzeybek, Betul Bolat
Akbarpour, Mahdi
Kayacik, Nurcin
Sagol, Ozgul
Ellidokuz, Hulya
Oztop, Ilhan
author_facet Baskin, Yasemin
Kocal, Gizem Calibasi
Kucukzeybek, Betul Bolat
Akbarpour, Mahdi
Kayacik, Nurcin
Sagol, Ozgul
Ellidokuz, Hulya
Oztop, Ilhan
author_sort Baskin, Yasemin
collection PubMed
description Most of the gastrointestinal stromal tumors (GISTs) have gain-of-function mutations in the KIT gene, which can be used as a prognostic marker for the biological behavior of tumors, predictive marker for the response of tyrosine kinase inhibitors, and diagnostic marker. Researchers have focused on PDGFRA mutations because of both their prognostic and predictive potential and DOG1 positivity for diagnosis on GISTs. The aim of this study is to investigate the effect DOG1, PDGFRA, and KIT mutations on the prediction of the outcome for GIST management. Polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17 and PDGFRA gene exons 12 and 18 with the genomic DNA of 46 GIST patients, and amplicons were sequenced in both directions. Immunocytochemical stainings were done by using primary antibodies. Molecular analysis revealed that the KIT mutation was observed in 63% of all cases, while the PDGFRA mutation was observed in 23.9% of cases. Significant relationships were found between age and KIT mutation, tumor location and KIT mutations, and tumor location and PDGFRA mutations (p ≤ 0.05). DOG1 positivity was detected in 65.2% of all GISTs and DOG1-positive cells had a higher KIT mutation ratio than DOG1-negative cells (p ≤ 0.05). KIT gene exon 11 mutations in DOG1-positive cells was higher than DOG1-negative cells (p ≤ 0.05). Conversely, KIT gene exon 13 mutations were higher in DOG1-negative cells than DOG1-positive cells (p ≤ 0.05). In this study, KIT mutation frequency was found similar with the European population; conversely, PDGFRA mutation frequency was similar with an Asian-Chinese-based study. KIT/PDGFRA mutations and tumor location can be used for the prediction of tumor behavior and the management of disease in GISTs. DOG1 positivity might be a candidate marker to support KIT and PDGFRA mutations, due to the higher DOG1 positivity in KIT exon 11 mutant and stomach- and small intestine-localized GISTs.
format Online
Article
Text
id pubmed-7838738
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cognizant Communication Corporation
record_format MEDLINE/PubMed
spelling pubmed-78387382021-02-16 PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1 Baskin, Yasemin Kocal, Gizem Calibasi Kucukzeybek, Betul Bolat Akbarpour, Mahdi Kayacik, Nurcin Sagol, Ozgul Ellidokuz, Hulya Oztop, Ilhan Oncol Res Article Most of the gastrointestinal stromal tumors (GISTs) have gain-of-function mutations in the KIT gene, which can be used as a prognostic marker for the biological behavior of tumors, predictive marker for the response of tyrosine kinase inhibitors, and diagnostic marker. Researchers have focused on PDGFRA mutations because of both their prognostic and predictive potential and DOG1 positivity for diagnosis on GISTs. The aim of this study is to investigate the effect DOG1, PDGFRA, and KIT mutations on the prediction of the outcome for GIST management. Polymerase chain reaction was performed for KIT gene exons 9, 11, 13, and 17 and PDGFRA gene exons 12 and 18 with the genomic DNA of 46 GIST patients, and amplicons were sequenced in both directions. Immunocytochemical stainings were done by using primary antibodies. Molecular analysis revealed that the KIT mutation was observed in 63% of all cases, while the PDGFRA mutation was observed in 23.9% of cases. Significant relationships were found between age and KIT mutation, tumor location and KIT mutations, and tumor location and PDGFRA mutations (p ≤ 0.05). DOG1 positivity was detected in 65.2% of all GISTs and DOG1-positive cells had a higher KIT mutation ratio than DOG1-negative cells (p ≤ 0.05). KIT gene exon 11 mutations in DOG1-positive cells was higher than DOG1-negative cells (p ≤ 0.05). Conversely, KIT gene exon 13 mutations were higher in DOG1-negative cells than DOG1-positive cells (p ≤ 0.05). In this study, KIT mutation frequency was found similar with the European population; conversely, PDGFRA mutation frequency was similar with an Asian-Chinese-based study. KIT/PDGFRA mutations and tumor location can be used for the prediction of tumor behavior and the management of disease in GISTs. DOG1 positivity might be a candidate marker to support KIT and PDGFRA mutations, due to the higher DOG1 positivity in KIT exon 11 mutant and stomach- and small intestine-localized GISTs. Cognizant Communication Corporation 2016-05-11 /pmc/articles/PMC7838738/ /pubmed/27178821 http://dx.doi.org/10.3727/096504016X14576297492418 Text en Copyright © 2016 Cognizant, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.
spellingShingle Article
Baskin, Yasemin
Kocal, Gizem Calibasi
Kucukzeybek, Betul Bolat
Akbarpour, Mahdi
Kayacik, Nurcin
Sagol, Ozgul
Ellidokuz, Hulya
Oztop, Ilhan
PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title_full PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title_fullStr PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title_full_unstemmed PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title_short PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
title_sort pdgfra and kit mutation status and its association with clinicopathological properties, including dog1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838738/
https://www.ncbi.nlm.nih.gov/pubmed/27178821
http://dx.doi.org/10.3727/096504016X14576297492418
work_keys_str_mv AT baskinyasemin pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT kocalgizemcalibasi pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT kucukzeybekbetulbolat pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT akbarpourmahdi pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT kayaciknurcin pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT sagolozgul pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT ellidokuzhulya pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1
AT oztopilhan pdgfraandkitmutationstatusanditsassociationwithclinicopathologicalpropertiesincludingdog1